AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06617221 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allograft
Description: after tooth extraction the socket was grafted with allograft
Study NCT06617156 — intervention group
Intervention type: OTHER
Intervention: RSBI Value Evaluation
Description: Spirometer Measurement: The traditional method for calculating RSBI involves the use of a spirometer (Wright MK20; Ferraris Medical Ltd., Hertford, England), equipped with a disposable bacterial filter at the front end, connected to the artificial airway to measure the minute ventilation of the patient's spontaneous breathing over one minute.~Three Measurement Methods from the Ventilator: A. PSV at 5 cmH2O with PEEP at 5 cmH2O B. CPAP at 5 cmH2O C. CPAP at 0 cmH2O.~Electrical impedance tomography (EIT) will be secured around the patient's thorax using a silicone belt, positioned at the fifth or sixth intercostal space, with 16 evenly spaced electrodes. Measurement data will be obtained by passing a small electrical current around the chest, utilizing the principle of resistance.
Study NCT06010238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short term variation
Description: Short term variation in computer software analysis
Study NCT06010238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visual interpretation
Description: Visual interpretation of cardiotocography
Study NCT06621095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib + benmelstobart + nab-paclitaxel + gemcitabine
Description: 1. Before 8 cycles, anlotinib 8mg, po.qd, d1-14; benmelstobart: 1200mg, I.V., D1, Q3W; nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The above schemes are repeated every three weeks.~2. After 8 cycles, the regimen is changed to anlotinib 8mg, po.qd, d1-14; benmelstobart: 1200mg, I.V., D1, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity.
Study NCT06621095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel + gemcitabine
Description: 1. Before 8 cycles, nab-paclitaxel: 125mg/m2, I.V., D1, D8, Q3W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The above schemes are repeated every three weeks.~2. After 8 cycles, the regimen is changed to gemcitabine: 1000/m2, ivgtt for more than 30min, D1, D8, Q3W. The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity.
Study NCT06620497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stress free implant bar
Description: SFI bar was sectioned and adjusted on the model for more convenience and to save the time of the appointment. The bar (Cendres Metaux, Switzerland) abutments were screwed to the implant analogues.
Study NCT06620497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: milled bar
Description: bar abutments were attached to the analogues and scan bodies were threaded into the bar abutments. The cast was scanned using a lab scanner (Ceramill, Amann Girrbach, Germany). The milled bar was selected from the software (Exocad DentalCAD) and designed digitally to connect the implants.
Study NCT06622980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The educational intervention will take the form of a video explaining both general ergonomic principles and specific advice for laparoscopic surgeons. This video will be shown to surgeons at a time of their convenience and the research team will be available to answer any further questions at this time.~The educational video will cover both ergonomics principles and specific advice for laparoscopic surgeons. The principles will be relevant to any situation, including those outside the medical field. The laparoscopic-specific section will include tips for optimisation of operating theatre set-up and advice on posture and body position. The video content will be reviewed by experts experienced in surgical ergonomics education to ensure it covers all useful information and is in line with best practice.
Study NCT06621927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: The Ideal Food Pyramid, which has not been applied before, is used to observe disease activities and especially changes in intestinal microbiota in rheumatoid arthritis.
Study NCT06621927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (Standard treatment)
Description: We chose a control group to show the effect of the intervention we would apply to the diet group and did not apply any intervention to the control group.
Study NCT06617871 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Alignment (MA)
Description: Primary TKA with the Medacta SpheriKA, utilizing either MA methodology.
Study NCT06617871 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kinematic Alignment (KA) Interventions:
Description: Primary TKA with the Medacta SpheriKA, utilizing either KA methodology.
Study NCT06618820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: One dose consists of three 650 milligram (mg) capsules, to be taken orally.
Study NCT06618820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose consists of three microcrystalline cellulose capsules.
Study NCT06618820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose consists of three microcrystalline cellulose capsules.
Study NCT06668012 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palomacare® vaginal gel is a medical device with CE class IIa.
Description: The duration of the study for each patient will be approximately 11-12 days and the treatment for groups A and B will be 6 days.~In a first pilot study in asymptomatic women, a tendency towards a positive effect on the composition of vaginal fluid was already observed, as assessed by diagnostic tests and classified using a Likert scale. A subsequent study showed that treatment with a different vaginal gel but with an identical concentration of ingredients from Palomacare® vaginal gel, for 21 consecutive days, is able to improve the composition of vaginal fluid.~Based on these preliminary data, it is possible to hypothesize that the action of Palomacare® vaginal gel will have a positive effect on the composition of vaginal fluid in patients affected by dysbiosis, whether asymptomatic or not.
Study NCT04737772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QL Marijuana Check-Up intervention (QL-MJCU)
Description: QL Marijuana Check-Up intervention (QL-MJCU) was developed for non-treatment seeking MJ users and is based on Motivational Enhancement Therapy. Includes TAU (see standard quitline arm) with a trained coach plus a MJ assessment and Personalized Feedback Report (PFR).
Study NCT04818606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Oriented Recovery Enhancement
Description: Participants randomized to the intervention group will undergo an eight-week mindfulness training program as instructed by MORE for the Treatment of Chronic Pain manual. This eight-week intervention will consist of weekly synchronous video conferencing sessions during which participants will be asked to follow along with a guided meditation read by the study lead and to engage in reflection and discussion exercises with other study participants. Participants will also be asked to complete weekly activities and daily mindfulness practices outside of weekly synchronous meetings.
Study NCT06621342 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PRP Experimental
Description: All participants will have 5 2ml tubes of blood collected at 72 +/- 5 hr prior to embryo transfer and again at 48 +/- 5 hour prior to embryo transfer. This blood will be processed to create PRP for the uterine infusion per protocol.
Study NCT06621342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP Experimental
Description: All participants will have 5 2ml tubes of blood collected at 72 +/- 5 hr prior to embryo transfer and again at 48 +/- 5 hour prior to embryo transfer. This blood will be processed to create PRP for the uterine infusion per protocol.
Study NCT06622772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valsalva assist device
Description: A valsalva assist device designed to provide the recommended resistance to exhalation at a pressure of 40 mmHg.
Study NCT06622772 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard Valsalva manoeuvre
Description: The Valsalva manoeuvre is carried out without any device.
Study NCT06623747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: 15 kcal per kg fat-free mass
Study NCT06623747 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: 45 kcal per kg fat-free mass
Study NCT06624930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioural Counselling
Description: The PA+BC group will receive a behavioural counselling support session with a QEP every two weeks during the intervention period (12 total). Of the 12 video-conferencing calls, one session will target reflective processes (instrumental/affective attitudes), five sessions will target behavioural regulation (action planning, coping planning, social support, goal setting), and four sessions will target reflexive processing (self-regulation, habit). The remaining two sessions are booster sessions to revisit topics discussed. The importance of sustaining PA for clinical outcomes (e.g., fatigue) and PA logs will be stressed. At the end of the 6-month program, an individualized PA prescription will be provided based on their fitness level (adjusted throughout) to continue achieving the PA goal for the 6-month post intervention and 1-year post intervention follow-up.
Study NCT06624930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Counselling
Description: The PA+EC group will receive the same frequency of group-based and 1:1 counseling support sessions via Zoom as PA+BC participants. However, the focus will be on exercise training principles for proper PA technique, how to monitor intensity, and progress PA safely to achieve the PA guidelines.
Study NCT06618560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel Matrix Derivative application
Description: After submarginal instrumentation (i.e., titanium curettes plus oscillating chitosan brush), implant surfaces will be conditioned for 2 min with 24% ethylene-diaminetetraacetate EDTA (PrefGel®, Institut Straumann AG). Then, the sites will be completely rinsed with saline solution and thoroughly dried with air. Repeated irrigation and air-drying will be done in the area until complete bleeding control with sterile gauzes. Then EMD (Emdogain®, Institut Straumann AG) will be gently applied with a blunt-tipped sterile syringe until overflowing from the mucosal margin.
Study NCT06618560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid (HA)
Description: After submarginal instrumentation of the implant surface (i.e., titanium curettes plus oscillating chitosan brush), the cross-linked hyaluronic acid gel composed of a mixture of cross-linked (1.6%) and natural (0.2%) will be will be implemented to the peri-implant pockets.
Study NCT06618560 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Implants allocated to the control group will be treated with the same sub-marginal instrumentation (i.e., titanium curettes plus oscillating chitosan brush). Implant surface will be irrigated with with sterile saline.
Study NCT06621680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multivitamins
Description: All participants will receive multivitamins (vitatron) capsule once daily, for 12 weeks.
Study NCT06621680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins
Description: All participants will receive multivitamins (vitatron) capsule once daily, for 12 weeks.
Study NCT06621680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective tissue massage
Description: Connective tissue massage will be applied on (Sacral, lumbar, last thoracic vertebrae-T12, and subcostal regions), 2 sessions/week for 20 minutes each session for 12 weeks. Treatment will begin 3 days before menstruation to the 4th day of menstruation for 3 successive menstrual cycles.
Study NCT05448365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol
Description: The patients will take for three months two tablets per day each containing 150mg epigallocatechin gallate, 25 mg D-chiro-inositol, 5mg Vitamin B6 and 25μg Vitamin D
Study NCT05448365 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrines
Study NCT05121051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood, buccal cell, and nasal epithelial cell samples
Study NCT05121051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood, buccal cell, and nasal epithelial cell samples
Study NCT05121051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout/Broccoli Seed Extract Supplement
Description: Given PO
Study NCT05121051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT05121051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05121051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01896947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: evaluating to see if 3T MRI is as effective as MR arthrogram to diagnose labral pathology
Study NCT05013879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio(R)Tape for edema control
Description: Kinesio(R)Tape is an elastic, cotton tape with an adhesive backing. When applied for edema management, strips of Kinesio(R)Tape are applied to the lower leg in a criss-cross fashion by a physical therapist who is a Certified Kinesiotape Practitioner.
Study NCT05954845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biopsies
Description: Biopsies will be obtained from the right and left colon (5 biopsies per colic region)
Study NCT06308029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth self-management support program
Description: This web-based eHealth program consists of two parts. First participants will complete a pain science education program. After being primed in the educational program, barriers for a physically active lifestyle should be removed and participants should be able to apply the learned information in the second part. The second part of the self-management support program consists of daily activity planning and strategies to promote an active lifestyle. The eHealth program will be accessible from any digital device (laptop, tablet, smartphone) after receiving a personal login code provided by the researcher. Participants go through the eHealth program independently at their own pace. It is recommended to do this in 8-12 weeks.
Study NCT06308029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face rehabilitation program
Description: The face-to-face rehabilitation program combines pain science education with an active behavioral approach. First, 2-3 individual face-to-face sessions are organized with a physical therapist to provide pain science education. The content of this pain science education program is the same as for the eHealth program. Similar as in the eHealth program, this education intervention includes advice for activity management, while experiencing pain and other symptoms, in order to remove barriers for an active lifestyle. The educational information will be presented verbally and written. After the education, the physical therapist will discuss proper goal setting with the patient to reach an active lifestyle and will coach the participant to reach these goals with maximum 6 face-to-face sessions. It is recommend to organise the in total 9 face-to-face sessions within a periode of 8-12 weeks.
Study NCT06499610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride Liposome Injection
Description: At the dose of 70mg / m2, for patients homozygous for UGT1A1 \* 28, the first dose of irinotecan was adjusted to 50mg / m2,70mg / m2 if the patient tolerated during the first cycle and 70 mg / m 2 in the subsequent cycle; add 500 mL of 5% glucose injection or 0.9% sodium chloride injection for intravenous infusion within 90 minutes. On the first day of each treatment cycle.
Study NCT05071040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based physical activity
Description: Participants will follow a strength exercise program
Study NCT05568615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Suspension
Study NCT05680675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single-Tracer FDG PET/CT Exam
Description: The PET technologist will administer approximately 15 millicuries (mCi) of FDG intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.
Study NCT05680675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single-Tracer Cu64-DOTATATE PET/CT Exam
Description: The PET technologist will administer with approximately 4 mCi Cu64-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.
Study NCT05680675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single-Tracer Ga68-DOTATATE PET/CT Exam
Description: The PET technologist will administer with with approximately 5 mCi Ga68-DOTATATE intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.
Study NCT05680675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single-Tracer PSMA PET/CT Exam
Description: The PET technologist will administer with with approximately 7 mCi Ga68-PSMA-11 intravenously, and the participant will remain resting during the tracer uptake period. A CT topogram will be obtained, and the PET imaging field-of-view (FOV) selected. The PET scan will then be acquired, acquiring 5 back-to-back whole-body (eyes-to-thighs, or similar) scans, providing 5 sequential PET images.
Study NCT06275425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with Byfavo
Description: General anesthesia is maintained with intravenous continuous administration of Byfavo.
Study NCT06275425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation anesthesia with Sevoflurane
Description: General anesthesia is maintained with Sevoflurane.
Study NCT04741802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TOPS
Description: weight loss program (Take Off Pounds Sensibly, TOPS) for overweight and obese African American breast cancer survivors in the local chapter of a national African American breast cancer support group (Sisters Network Triangle North Carolina, SNTNC).
Study NCT06163352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: The sample consisted of all medical and surgical patients over 18 who do not have pressure injury upon admission and received one or more vasopressor agent infusions (norepinephrine, epinephrine, dopamine) for at least 48 hours during their stay in the ICU and pressure injury development was assessed. The effect of combined use of more than one vasopressor agent on the development of pressure injury was investigated, considering the type and quantity of vasopressors (norepinephrine and dopamine), vasopressor combinations, total duration of infusion, and doses of vasopressors used.
Study NCT06163352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: The sample consisted of all medical and surgical patients over 18 who do not have pressure injury upon admission and received one or more vasopressor agent infusions (norepinephrine, epinephrine, dopamine) for at least 48 hours during their stay in the ICU and pressure injury development was assessed. The effect of combined use of more than one vasopressor agent on the development of pressure injury was investigated, considering the type and quantity of vasopressors (norepinephrine and dopamine), vasopressor combinations, total duration of infusion, and doses of vasopressors used.
Study NCT05208385 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: video-assisted umbilical closure
Description: video-assisted umbilical closure
Study NCT05208385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: video-assisted umbilical closure
Description: video-assisted umbilical closure
Study NCT06371365 — intervention group
Intervention type: PROCEDURE
Intervention: Free Flap surgery
Description: No intervention, this is an observational study
Study NCT05351619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: oral care bundle implementation
Description: oral care bundle encompasses oral assessment, tooth brushing, oral / lip moisturization, and suctioning oropharyngeal secretions above the cuff.